Sugi Predict

Sugi Predict / Targets / RASGRP3

RASGRP3

Ras guanyl-releasing protein 3 · Q8IV61 · RASGRP3 on Sugi Atlas →

1,709 patent compounds predicted against RASGRP3, 929 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL12096550 SCHEMBL12096550 0.39 6/20
SCHEMBL12096551 SCHEMBL12096551 0.39 6/20
SCHEMBL12172299 SCHEMBL12172299 0.39 6/20
SCHEMBL12096519 SCHEMBL12096519 0.36 6/20
SCHEMBL12096521 SCHEMBL12096521 0.36 6/20
SCHEMBL6060764 SCHEMBL6060764 0.54 5/20
SCHEMBL21309889 SCHEMBL21309889 0.39 4/20
SCHEMBL2993832 SCHEMBL2993832 0.39 4/20
SCHEMBL2993836 SCHEMBL2993836 0.39 4/20
SCHEMBL3002939 SCHEMBL3002939 0.39 4/20
SCHEMBL3002941 SCHEMBL3002941 0.39 4/20
SCHEMBL21518977 SCHEMBL21518977 0.31 4/20
SCHEMBL2134416 SCHEMBL2134416 0.56 3/20
SCHEMBL196342 SCHEMBL196342 0.50 3/20
SCHEMBL3899546 SCHEMBL3899546 0.50 3/20
SCHEMBL3903585 SCHEMBL3903585 0.50 3/20
SCHEMBL15980753 SCHEMBL15980753 0.44 3/20
SCHEMBL5822258 SCHEMBL5822258 0.41 3/20
SCHEMBL5822263 SCHEMBL5822263 0.41 3/20
SCHEMBL14802656 SCHEMBL14802656 0.33 3/20

Clinical trials — most relevant to RASGRP3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1 PHASE2COMPLETED
Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1 PHASE2COMPLETED
NEO100 and High-Grade Meningioma PHASE2RECRUITING
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma PHASE1/PHASE2SUSPENDED
Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC) PHASE2COMPLETED
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma PHASE1ACTIVE_NOT_RECRUITING
Expression and Function of the Renin-Angiotensin System in the Esophagus EARLY_PHASE1COMPLETED
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial nanRECRUITING
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients nanCOMPLETED
Genetics of Hypertension in Blacks nanCOMPLETED
Prevalence and Characterization of Pain in RASopathies nanUNKNOWN
Characterisation of Gene Variants in the Angiogenic Pathway nanUNKNOWN
Long QT Syndrome-Population Genetics and Cardiac Studies nanCOMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
RASopathy Biorepository nanRECRUITING
Thrombin Regulated Platelet Activation nanCOMPLETED
Exploring the Genetics of Neuropathic Pain nanRECRUITING
Influence of Genetic Polymorphisms on Ventricular Structure and Function in Patients With Single Ventricle Anatomy nanCOMPLETED
Renal Artery Dopplers in Twin Twin Transfusion Syndrome nanCOMPLETED
Study of the Genetic and Epigenetic Causes of Recurrent Hydatidiform Moles nanACTIVE_NOT_RECRUITING
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins. nanUNKNOWN
Circulating Biomarker Signatures for the Detection of Gastric Preneoplasia and Cancer nanRECRUITING
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity nanNOT_YET_RECRUITING
Genetics and Psychopathology in the 22q11 Deletion Syndrome nanUNKNOWN
Association Between a Multi-Gene Panel and Renal Denervation Effectiveness in Patients With Hypertension nanUNKNOWN
Genetic Registry for Rheumatoid Arthritis nanCOMPLETED
CML Pediatric ITK Response According to Molecular Identification at Diagnosis nanRECRUITING
An Investigation of Small Intestinal Carcinoid Carcinoma in Families nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a RASGRP3 binder may also engage these)

ProteinNameSimilarity
P0C643 — 0.997 P0C643 →
A6N9I4 — 0.996 A6N9I4 →
Q60695 — 0.991 Q60695 →
Q32N25 — 0.990 Q32N25 →
Q9NZL6 — 0.989 Q9NZL6 →
Q9CXF4 — 0.989 Q9CXF4 →
Q9ERD6 — 0.988 Q9ERD6 →
Q91WS7 — 0.988 Q91WS7 →
F1MSG6 — 0.986 F1MSG6 →
Q7LDG7 — 0.986 Q7LDG7 →
B0UXH6 — 0.986 B0UXH6 →
Q86X27 — 0.986 Q86X27 →
A2AR50 — 0.986 A2AR50 →
Q1JQ19 — 0.985 Q1JQ19 →
Q8K0Q5 — 0.985 Q8K0Q5 →
Q9NXL2 — 0.985 Q9NXL2 →
Q4R623 — 0.985 Q4R623 →
Q9QUG9 — 0.985 Q9QUG9 →
O75815 — 0.984 O75815 →
Q6P112 — 0.984 Q6P112 →
Q5R8B7 — 0.984 Q5R8B7 →
Q9Y4G8 — 0.984 Q9Y4G8 →
O14830 — 0.984 O14830 →
Q9ERS4 — 0.983 Q9ERS4 →
Q5SVR0 — 0.983 Q5SVR0 →
Q812E4 — 0.983 Q812E4 →
Q14B46 — 0.983 Q14B46 →
Q8C0M0 — 0.983 Q8C0M0 →
Q8CHG7 — 0.983 Q8CHG7 →
Q8BN58 — 0.983 Q8BN58 →